#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hypergammaglobulinaemia benign monoclonal Pemphigus Adenovirus infection Neuroendocrine tumour Medullary thyroid cancer Astrocytoma malignant Cerebellar ataxia Eosinophilic oesophagitis Desmoid tumour Mucopolysaccharidosis III Brain stem glioma Central nervous system neoplasm Polycystic liver disease NTRK gene fusion overexpression Immune-mediated renal disorder More trials…

    Learn about Rare Diseases

    Fragile X syndrome – Treatment Mucous membrane pemphigoid – Treatment Vascular malformation – Basic Information Skin angiosarcoma – Trials in Disease Systemic mastocytosis Primary biliary cholangitis – Treatment Hereditary angioedema – Trials in Disease Adrenocortical carcinoma – Basic Information Haemophilia A with anti factor VIII – Trials in Disease Familial amyotrophic lateral sclerosis – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Azelastine CICLOPIROX Amoxicillin Sodium Mannitol ZELENECTIDE PEVEDOTIN 2,4 DICHLOROBENZYL ALCOHOL Ibrutinib Norfloxacin PROMESTRIENE Palonosetron METHYLPHENIDATE Rbd5044 Sodium ANGIOTENSIN II Nepafenac Aaa802 FG001 Liraglutide Revumenib Ipilimumab Obeticholic Acid More therapies…

    Learn about Your Condition

    Alagille syndrome Arrhythmia Myelodysplastic syndrome Ulcerative keratitis Kaposi's sarcoma Bladder cancer recurrent Follicular thyroid cancer Hypotransferrinaemia Gingival bleeding Gouty arthritis Mechanical ventilation Chronic sinusitis Hypothyroidism Pre-eclampsia Tympanic membrane hyperaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hepatitis D

  • Study on the Effects of Tobevibart and Elebsiran Compared to Bulevirtide for Patients with Chronic Hepatitis D Virus Infection

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hepatitis B
    • Hepatitis D
    Investigated Drugs:
    • Bulevirtide
    • Elebsiran
    • Tobevibart
    Belgium Bulgaria France Germany Italy The Netherlands +2

  • Study on Tobevibart and Elebsiran for Patients with Chronic Hepatitis D Virus Infection Not Responding to Bulevirtide Treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hepatitis B
    • Hepatitis D
    Investigated Drugs:
    • Bulevirtide
    • Elebsiran
    • Tobevibart
    Austria France Germany Italy Romania Spain

  • Study on Tobevibart and Elebsiran for Patients with Chronic Hepatitis D Virus Infection

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hepatitis B
    • Hepatitis D
    Investigated Drugs:
    • Elebsiran
    • Tobevibart
    France Germany Romania

  • Study on the Effects of VIR-2218 and VIR-3434 for Patients with Chronic Hepatitis D Infection

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Hepatitis B
    • Hepatitis D
    Investigated Drugs:
    • Elebsiran
    • Tobevibart
    Bulgaria France Germany Italy The Netherlands Romania

  • Study on the Effectiveness and Safety of JNJ-73763989 and Tenofovir Alafenamide in Patients with Hepatitis B and D Co-infection

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Hepatitis B
    • Hepatitis D
    Investigated Drugs:
    • Daplusiran
    • Tomligisiran
    • Entecavir
    France Italy Sweden

  • Study on the Effects of RBD1016 and Tenofovir Alafenamide for Patients with Chronic Hepatitis D Infection

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Hepatitis D
    Investigated Drugs:
    • Rbd1016
    • Tenofovir Alafenamide
    Sweden
Previous Page
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!